
N-Lorem accepted Ireland as a patient in 2021. They have made incredible progress on the research and development of a personalized medicine for her. Ireland's program is estimated to cost $1.2 million. N-Lorem is a nonprofit and generously provides their medicines for free, for the life of the patient.

Antisense Oligonucleotides (ASOs) are designed to bind precisely with RNA, modifying the process of creating a disease-causing protein. ASOs are short strands of modified DNA that can specifically target the transcripts of a defective gene to modify the product of that gene.
%20Tolbert-10-2022-Kristin_Boyer_IMG-6437.jpg/:/cr=t:23.71%25,l:27.53%25,w:35.24%25,h:70.42%25/rs=w:600,h:800,cg:true,m)
An ASO is a genetic based treatment that we hope will improve several of her symptoms and has the possibility to slow the progression of her neurodegenerative disease. 7/7 N-Lorem patients show evidence of clinically important benefit with no adverse reactions.